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The use of a systemic therapy in completely resected non-small
cell lung cancer (NSCLC) is reasonably justified by follow-up
studies after radical resection that have shown the high
proportion of distant failures over local recurrences.
Earlier trials testing the role of alkylating agents and non-
specific immunotherapies uniformly failed to demonstrate any
survival benefit [1].
A second series of adjuvant trials, almost all of them
cisplatin-based, were subsequently performed and, in a couple
of studies some benefit for adjuvant chemotherapy was
observed. Common findings in these studies include the
overestimation of the potential benefit of adjuvant
chemotherapy, in some trials an unbalance in patients’ and
treatment characteristics and, for most of these studies, the
impossibility of reaching the planned accrual [1].
In 1995, a meta-analysis performed in different subgroups of
NSCLC receiving chemotherapy, overviewed eight cisplatin-
based adjuvant chemotherapy trials in 1394 patients and
demonstrated a 13% reduction of the risk of death which was
close to the borderline of statistical significance (P = 0.08).
On the other hand, adjuvant chemotherapy with long term
alkylating agents was significantly detrimental [2].
These findings failed to impact on clinical practice not
because the absolute gain was too small but because such an
estimate was still imprecise, ranging from 1% detriment to
a 10% benefit. In addition the heterogeneity of surgical
procedures and the difference in the staging modalities
strongly limited the applicability of the results of this
meta-analysis.
This 5-year survival benefit of the above mentioned
NSCLC meta-analysis, which was not statistically significant,
generated enough enthusiasm to prompt the planning
of several randomised studies, all platinum-based (± thoracic
radiotherapy), in completely resected NSCLC stages
I-II-IIIa.
More or less at the same time several Japanese studies
investigated the role of UFT (a combination of tegafur and
uracil at a molar ratio of 1:4) as adjuvant treatments, alone or in
combination with other agents, ending in conflicting results. At
the beginning of 2004, a large adjuvant phase III study which
tested UFT for 2 years versus control in resected stage I
adenocarcinoma of the lung was published and the results at
5 years showed a modest, but significant overall survival benefit
(P = 0.035) for UFT-treated patients that was essentially
confined to T2 patients (P = 0.051) [3].
Although a meta-analysis of six of these UFT studies
became recently available [4] supporting a role for UFT as
an adjuvant treatment, the absence of any advantage in
disease-free survival for all UFT-treated arms, clearly contrast
with the results of the recently reported positive, cisplatin-based
adjuvant studies (IALT, NCIC-BR10, CALGB 8633, ANITA)
where improvement in overall survival for patients receiving
adjuvant chemotherapy was invariably associated with
a similar or greater magnitude in disease-free survival. In
addition it should be noted that UFT has been proven to be
inactive in advanced disease [5].
Coming to the positive impact on 5-year survival rate of
cisplatin-based, adjuvant chemotherapy as recently reported
in 4 trials [6–9] the benefit ranged from 4.1% (IALT) to
almost 15% (NCIC-BR 19). How we can explain such huge
range of benefit, why such benefit was not uniformly observed
across all stages in some studies (for instance in NCIC-BR19
the benefit was seen in stage II but not in stage IB while in
IALT most of the benefit was confined to stage III) and how
strong are the statistical considerations about these results
(IALT and CALGB were closed before enrolling the original
number of patients)?
There is a general tendency to compare cross-sectionally
the benefit of adjuvant chemotherapy in NSCLC with that
previously observed in other types of solid tumor (breast and
colon cancers). However, specifically for NSCLC several
potential confounding factors should be carefully taken into
consideration. Firstly, all these adjuvant studies enrolled
a selected patient population of which we do not know how
much is representative of the whole population of completely
resected NSCLC patients. Secondly, in many of these studies
no information is available about the proportion of patients
who during surgical resection underwent systematic lymph
nodal dissection or mediastinal lymph node sampling. Thirdly,
lung cancer patients frequently suffer from comorbidities,
including chronic obstructive pulmonary disease and
cardiovascular diseases that were found to affect significantly
survival [10–11]. Additionally, an unbalance in the
proportion of patients who potentially quit smoking after
radical surgery may potentially account for survival
differences [12]. Survival differences between ever smokers
and never smokers have been recently documented also in
another tobacco-related cancer [13].
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In conclusion although information in favour of adjuvant
chemotherapy in completely resected NSCLC is available,
more detailed analyses of the results of recent positive trials
are needed to reasonably conclude that adjuvant chemotherapy
is recommended for every patient who undergone radical
surgery for early NSCLC and to exclude the potential of
biases related to confounding factors.
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